Tiago Fauth
Stock Analyst at Wells Fargo
(2.11)
# 2,998
Out of 5,042 analysts
151
Total ratings
40%
Success rate
-5.25%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Maintains: Overweight | $21 → $18 | $7.13 | +152.45% | 4 | Sep 4, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $295 → $414 | $418.58 | -1.09% | 7 | Sep 3, 2025 | |
| MNKD MannKind | Maintains: Overweight | $9 → $10 | $5.31 | +88.32% | 2 | Sep 3, 2025 | |
| INSM Insmed | Maintains: Overweight | $140 → $171 | $159.66 | +7.10% | 8 | Sep 3, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $79 → $73 | $66.40 | +9.94% | 5 | Aug 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $22.38 | +38.52% | 3 | Aug 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $463.43 | -14.77% | 7 | Aug 1, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $33.53 | +93.86% | 8 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $54.26 | +40.07% | 1 | Jun 30, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $4.36 | +60.55% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $17.15 | +488.92% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.81 | +65.75% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $15.04 | +72.87% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $8.67 | +96.08% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $85.63 | -12.41% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $5.81 | +967.13% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $202.00 | -55.94% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $22.16 | +130.14% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $54.48 | +120.26% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $18.94 | -78.88% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $4.27 | +227.87% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $133.24 | +125.16% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $9.70 | +168.04% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $5.66 | +394.70% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $28.17 | +187.54% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.76 | +952.63% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $3.46 | +304.62% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $1.75 | +1,842.86% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $8.43 | +1,679.36% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $38.72 | -25.10% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.63 | +697.55% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $3.72 | +249.46% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $1.40 | +42.86% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $817.32 | -58.40% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $291.76 | -11.23% | 1 | Apr 28, 2021 |
Wave Life Sciences
Sep 4, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $7.13
Upside: +152.45%
United Therapeutics
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $295 → $414
Current: $418.58
Upside: -1.09%
MannKind
Sep 3, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $5.31
Upside: +88.32%
Insmed
Sep 3, 2025
Maintains: Overweight
Price Target: $140 → $171
Current: $159.66
Upside: +7.10%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $79 → $73
Current: $66.40
Upside: +9.94%
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $22.38
Upside: +38.52%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $463.43
Upside: -14.77%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $33.53
Upside: +93.86%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $54.26
Upside: +40.07%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $4.36
Upside: +60.55%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $17.15
Upside: +488.92%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.81
Upside: +65.75%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $15.04
Upside: +72.87%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $8.67
Upside: +96.08%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $85.63
Upside: -12.41%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $5.81
Upside: +967.13%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $202.00
Upside: -55.94%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $22.16
Upside: +130.14%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $54.48
Upside: +120.26%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $18.94
Upside: -78.88%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $4.27
Upside: +227.87%
May 16, 2023
Reiterates: Outperform
Price Target: $300
Current: $133.24
Upside: +125.16%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $9.70
Upside: +168.04%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $5.66
Upside: +394.70%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $28.17
Upside: +187.54%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.76
Upside: +952.63%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $3.46
Upside: +304.62%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $1.75
Upside: +1,842.86%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $8.43
Upside: +1,679.36%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $38.72
Upside: -25.10%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.63
Upside: +697.55%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $3.72
Upside: +249.46%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $1.40
Upside: +42.86%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $817.32
Upside: -58.40%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $291.76
Upside: -11.23%